Mahboob Rahman1, Wei Yang2, Sanjeev Akkina3, Arnold Alper4, Amanda Hyre Anderson2, Lawrence J Appel5, Jiang He4, Dominic S Raj6, Jeffrey Schelling7, Louise Strauss8, Valerie Teal2, Daniel J Rader9. 1. Department of Medicine, Case Western Reserve University, University Hospitals Case Medical Center, Louis Stokes Cleveland Veterans Affairs Medical Center, Cleveland, Ohio; Mahboob.Rahman@uhhospitals.org. 2. Center for Clinical Epidemiology and Biostatistics and. 3. Division of Nephrology, University of Illinois, Chicago, Illinois; 4. Department of Epidemiology, Tulane University, New Orleans, Louisiana; 5. Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins University, Baltimore, Maryland; 6. Division of Nephrology, George Washington University, Washington, DC; 7. Case Western Reserve University, MetroHealth Medical Center, Cleveland, Ohio; and. 8. University Hospitals Case Medical Center, Cleveland, Ohio. 9. Division of Translational Medicine and Human Genetics, University of Pennsylvania, Philadelphia, Pennsylvania;
Abstract
BACKGROUND AND OBJECTIVES: Hyperlipidemia is common in patients with CKD. The objective of this study was to evaluate whether measures of plasma lipids and lipoproteins predict progression of kidney disease in patients with CKD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Prospective cohort study in adults (n=3939) with CKD aged 21-74 years recruited between 2003 and 2008 and followed for a median of 4.1 years. At baseline, total cholesterol, triglycerides, very-low-density lipoprotein cholesterol (VLDL-C), LDL cholesterol (LDL-C), HDL cholesterol (HDL-C), apoA-I , apoB, and lipoprotein(a) [Lp(a)] were measured. The outcomes were composite end point of ESRD or 50% decline in eGFR from baseline (rate of change of GFR). RESULTS: Mean age of the study population was 58.2 years, and the mean GFR was 44.9 ml/min per 1.73 m(2); 48% of patients had diabetes. None of the lipid or lipoprotein measures was independently associated with risk of the composite end point or rate of change in GFR. However, there were significant (P=0.01) interactions by level of proteinuria. In participants with proteinuria<0.2 g/d, 1-SD higher LDL-C was associated with a 26% lower risk of the renal end point (hazard ratio [HR], 0.74; 95% confidence interval [95% CI], 0.59 to 0.92; P=0.01), and 1-SD higher total cholesterol was associated with a 23% lower risk of the renal end point (HR, 0.77; 95% CI, 0.62 to 0.96; P=0.02). In participants with proteinuria>0.2 g/d, neither LDL-C (HR, 0.98; 95% CI, 0.98 to 1.05) nor total cholesterol levels were associated with renal outcomes. Treatment with statins was reported in 55% of patients and was differential across lipid categories. CONCLUSIONS: In this large cohort of patients with CKD, total cholesterol, triglycerides, VLDL-C, LDL-C, HDL-C, apoA-I, apoB, and Lp(a) were not independently associated with progression of kidney disease. There was an inverse relationship between LDL-C and total cholesterol levels and kidney disease outcomes in patients with low levels of proteinuria.
BACKGROUND AND OBJECTIVES:Hyperlipidemia is common in patients with CKD. The objective of this study was to evaluate whether measures of plasma lipids and lipoproteins predict progression of kidney disease in patients with CKD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Prospective cohort study in adults (n=3939) with CKD aged 21-74 years recruited between 2003 and 2008 and followed for a median of 4.1 years. At baseline, total cholesterol, triglycerides, very-low-density lipoprotein cholesterol (VLDL-C), LDL cholesterol (LDL-C), HDL cholesterol (HDL-C), apoA-I , apoB, and lipoprotein(a) [Lp(a)] were measured. The outcomes were composite end point of ESRD or 50% decline in eGFR from baseline (rate of change of GFR). RESULTS: Mean age of the study population was 58.2 years, and the mean GFR was 44.9 ml/min per 1.73 m(2); 48% of patients had diabetes. None of the lipid or lipoprotein measures was independently associated with risk of the composite end point or rate of change in GFR. However, there were significant (P=0.01) interactions by level of proteinuria. In participants with proteinuria<0.2 g/d, 1-SD higher LDL-C was associated with a 26% lower risk of the renal end point (hazard ratio [HR], 0.74; 95% confidence interval [95% CI], 0.59 to 0.92; P=0.01), and 1-SD higher total cholesterol was associated with a 23% lower risk of the renal end point (HR, 0.77; 95% CI, 0.62 to 0.96; P=0.02). In participants with proteinuria>0.2 g/d, neither LDL-C (HR, 0.98; 95% CI, 0.98 to 1.05) nor total cholesterol levels were associated with renal outcomes. Treatment with statins was reported in 55% of patients and was differential across lipid categories. CONCLUSIONS: In this large cohort of patients with CKD, total cholesterol, triglycerides, VLDL-C, LDL-C, HDL-C, apoA-I, apoB, and Lp(a) were not independently associated with progression of kidney disease. There was an inverse relationship between LDL-C and total cholesterol levels and kidney disease outcomes in patients with low levels of proteinuria.
Authors: Marshall Joffe; Chi-yuan Hsu; Harold I Feldman; Matthew Weir; J R Landis; L Lee Hamm Journal: Am J Nephrol Date: 2010-04-14 Impact factor: 3.754
Authors: Amanda Hyre Anderson; Wei Yang; Chi-yuan Hsu; Marshall M Joffe; Mary B Leonard; Dawei Xie; Jing Chen; Tom Greene; Bernard G Jaar; Patricia Kao; John W Kusek; J Richard Landis; James P Lash; Raymond R Townsend; Matthew R Weir; Harold I Feldman Journal: Am J Kidney Dis Date: 2012-06-02 Impact factor: 8.860
Authors: Caroline S Fox; Martin G Larson; Eric P Leip; Bruce Culleton; Peter W F Wilson; Daniel Levy Journal: JAMA Date: 2004-02-18 Impact factor: 56.272
Authors: Sebhat Erqou; Stephen Kaptoge; Philip L Perry; Emanuele Di Angelantonio; Alexander Thompson; Ian R White; Santica M Marcovina; Rory Collins; Simon G Thompson; John Danesh Journal: JAMA Date: 2009-07-22 Impact factor: 56.272
Authors: Sankar D Navaneethan; Francesca Pansini; Vlado Perkovic; Carlo Manno; Fabio Pellegrini; David W Johnson; Jonathan C Craig; Giovanni F M Strippoli Journal: Cochrane Database Syst Rev Date: 2009-04-15
Authors: Yongmei Liu; Josef Coresh; Joseph A Eustace; J Craig Longenecker; Bernard Jaar; Nancy E Fink; Russell P Tracy; Neil R Powe; Michael J Klag Journal: JAMA Date: 2004-01-28 Impact factor: 56.272
Authors: S Hadjadj; B Duly-Bouhanick; A Bekherraz; F BrIdoux; Y Gallois; G Mauco; Jm Ebran; M Marre Journal: Diabetes Metab Date: 2004-02 Impact factor: 6.041
Authors: James P Lash; Alan S Go; Lawrence J Appel; Jiang He; Akinlolu Ojo; Mahboob Rahman; Raymond R Townsend; Dawei Xie; Denise Cifelli; Janet Cohan; Jeffrey C Fink; Michael J Fischer; Crystal Gadegbeku; L Lee Hamm; John W Kusek; J Richard Landis; Andrew Narva; Nancy Robinson; Valerie Teal; Harold I Feldman Journal: Clin J Am Soc Nephrol Date: 2009-06-18 Impact factor: 8.237
Authors: Farsad Afshinnia; Viji Nair; Jiahe Lin; Thekkelnaycke M Rajendiran; Tanu Soni; Jaeman Byun; Kumar Sharma; Patrice E Fort; Thomas W Gardner; Helen C Looker; Robert G Nelson; Frank C Brosius; Eva L Feldman; George Michailidis; Matthias Kretzler; Subramaniam Pennathur Journal: JCI Insight Date: 2019-11-01